文献速递药物不良反应与药物警戒特殊人群用药肝肾功能剂量调整

胰高血糖素样肽-1受体激动剂安全性与耐受性:最新叙述性综述

Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review.
PubMed 文献 · Drugs · 2025-12-06

本文为叙述性综述,综合临床试验、药物警戒数据库和真实世界队列证据,评估GLP-1RAs及替尔泊肽的安全性与耐受性。胃肠道不良事件最常见,多发生于剂量递增期并随时间缓解;胆囊疾病、胃轻瘫、肠梗阻等需警惕。大规模证据不支持GLP-1RAs显著增加急性肾损伤风险,特殊人群安全性数据仍有限。

要点

  • 胃肠道不良事件最常见,多在剂量递增期出现并随时间缓解。
  • 需警惕胆囊疾病、胃轻瘫、肠梗阻及糖尿病视网膜病变恶化。
  • 大规模证据不支持GLP-1RAs显著增加急性肾损伤风险。

核心结论

  • GLP-1RAs及替尔泊肽治疗获益明确,但需个体化用药、谨慎选患者并持续安全性监测。

研究设计与样本

  • 叙述性综述,综合随机试验、荟萃分析、药物警戒数据库和真实世界队列证据。

主要发现

  • 恶心、呕吐、腹泻和便秘是最常见的不良事件,多在剂量递增期出现并随时间缓解。
  • 胆囊结石、胆囊炎、胃轻瘫和肠梗阻等胃肠道并发症的证据在积累,易感个体需谨慎。
  • 注射部位反应和既存糖尿病视网膜病变恶化是相关临床关注点。
  • 非动脉炎性前部缺血性视神经病变、胰腺炎、甲状腺髓样癌和急性肾损伤主要经药物警戒和病例证据报告,属罕见。
  • 大规模随机试验、荟萃分析和观察性研究提示GLP-1RAs不显著增加急性肾损伤风险,高危人群可能获益。

临床怎么用

  • 剂量递增期应重点监测胃肠道不良事件并采取缓解策略。
  • 对易感个体需警惕胆囊疾病、胃轻瘫和肠梗阻,并关注注射部位反应及视网膜病变变化。
  • 特殊人群(妊娠或哺乳期女性、儿童、晚期肾或肝功能不全者)安全性数据有限,用药需谨慎并进一步研究。

局限性

  • 妊娠或哺乳期女性、儿童及晚期肾或肝功能不全等特殊人群的安全性数据有限,需进一步研究。
  • 未来研究应优先关注代表性不足人群的长期安全性及减轻瘦体重丢失的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucagon-like peptide-1 receptor agonists (GLP-1RAs)-along with the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA tirzepatide-are widely acknowledged for their efficacy in managing both type 2 diabetes mellitus and obesity, with expanding indications in cardiometabolic risk reduction. While their glycemic, weight-lowering, and cardiovascular benefits are well established through randomized trials and meta-analyses, concerns remain regarding their safety and tolerability across diverse populations and clinical settings. Gastrointestinal (GI) adverse events-particularly nausea, vomiting, diarrhea, and constipation-are the most common side effects, generally emerging during dose escalation and resolving over time. However, accumulating evidence has identified additional GI complications, including cholelithiasis, cholecystitis, gastroparesis, and bowel obstruction, which may warrant caution in susceptible individuals. Injection-site reactions and worsening of pre-existing diabetic retinopathy are also relevant clinical concerns. Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence. Importantly, large-scale randomized trials, meta-analyses, and observational studies suggest that GLP-1RAs do not significantly increase AKI risk and may even confer renal benefits in high-risk populations. There is no confirmed elevated risk of suicidality, but surveillance remains warranted. Safety data in special populations-such as pregnant or lactating women, pediatric patients, and those with advanced renal or hepatic impairment-remain limited and require further study. This state-of-the-art narrative review synthesizes current evidence from clinical trials, pharmacovigilance databases, and real-world cohorts to provide a comprehensive evaluation of the safety and tolerability of GLP-1RAs and tirzepatide. We present clinical strategies for adverse event mitigation, monitoring recommendations, contraindications, and practical considerations for treatment discontinuation or switching. Although these agents offer transformative therapeutic potential, their optimal use requires individualized care, careful patient selection, and ongoing safety surveillance. Future research should prioritize long-term safety in underrepresented populations and strategies to mitigate lean mass loss during therapy.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Kunutsor SK, Seidu S. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review. Drugs. 2025. PMID: 41351656. doi:10.1007/s40265-025-02263-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。